AFAR Grantees in the News: David Sinclair, PhD, A.O., and Lindsay Wu, PhD, on NAD+ in clinical trials in Nature Aging
![AFAR Grantees in the News: David Sinclair, PhD, A.O., and Lindsay Wu, PhD, on NAD+ in clinical trials in Nature Aging]()
On September 9th, 2025, Nature Aging published an article co-authored by Irving S. Wright Award recipient and grantee David Sinclair, PhD, A.O., and AFAR Grantee Lindsay Wu, PhD, on recent advances in research exploring Nicotinamide adenine dinucleotide (NAD+) and its potential use as treatments for aging-related diseases. The paper highlights emerging techniques and their applications, as well as the challenges of using NAD+ in clinical trials.
Dr. Sinclair is a 2000 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and the 2018 Irving S. Wright Award recipient.
Dr. Wu is a 2022 Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipient.
Read “Emerging strategies, applications and challenges of targeting NAD+ in the clinic” here.